// App-Quantinova.ai

EP769 : BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH STAGE III OR IV HODGKIN LYMPHOMA: A SUBGROUP ANALYSIS FROM THE PHASE 3 ECHELON-1 STUDY

Researchers

Presenter

  • Andrew P. Grigg

Principal Investigators

  • Ann S. LaCasce

  • Nancy L. Bartlett

  • David J. Straus

  • Kerry J. Savage

  • Pier Luigi Zinzani

  • Graham P. Collins

  • Michelle A. Fanale

  • Keenan Fenton

  • Cassie Dong

  • Harry H. Miao

  • Howland E. Crosswell

Medical Centers

  • Clinical Haematology,Austin Hopsital,Austin, VIC,Australia

  • Seagen Inc.,Bothell, WA,United States

  • BC Cancer Agency, Vancouver, BC, Canada

  • Sanofi-Genzyme Oncology,Cambridge, MA,United States

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Bon Secours Hematology Oncology, Bon Secours St. Francis Health System, Greenville, SC

  • Siteman Cancer Center, Washington University School of Medicine in St. Louis, St. Louis, MO

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Dana-Farber Cancer Institute, Partners CancerCare,Boston, MA,United States

Locations

  • Australia

  • United States

  • Canada

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved